Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 4:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–12 of 12 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: ADHD - Combined Type Clear all
Recruiting Phase 4 Interventional
View directory record Official record
Conditions
ADHD - Combined Type
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
6 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced May 22, 2026, 4:09 AM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
ADHD, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined, Attention Deficit Hyperactivity Disorder
Interventions
CTx-1301 - Dexmethylphenidate 25mg, CTx-1301 - Dexmethylphenidate 37.5mg, CTx-1301 - Dexmethylphenidate 50mg, Placebo
Drug
Lead sponsor
Cingulate Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced May 22, 2026, 4:09 AM EDT
Not listed No phase listed Observational
View directory record Official record
Conditions
ADHD - Combined Type, ADHD, ADHD Predominantly Inattentive Type, ADHD, Predominantly Hyperactive - Impulsive
Interventions
EYE-SYNC
Device
Lead sponsor
Sync-Think, Inc.
Industry
Eligibility
6 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Carlos, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced May 22, 2026, 4:09 AM EDT
Not listed Phase 1 Interventional
View directory record Official record
Conditions
ADHD, Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder, ADD, ADHD Predominantly Inattentive Type, ADHD - Combined Type, ADHD, Predominantly Hyperactive - Impulsive, Attention-Deficit Disorder in Adolescence, Attention-Deficit Hyperactivity Disorder Symptoms, Attention-Deficit Hyperactivity Disorder
Interventions
Homework Organization and Planning Skills (HOPS) Intervention, Digital Health Application (Online Platform) for Encouraging Skills Practice
Behavioral · Device
Lead sponsor
Children's National Research Institute
Other
Eligibility
11 Years to 14 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced May 22, 2026, 4:09 AM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Meta-Cognitive Therapy, Supportive Therapy
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced May 22, 2026, 4:09 AM EDT
Suspended Phase 3 Interventional
View directory record Official record
Conditions
ADHD, ADHD - Combined Type, Attention Deficit Hyper Activity, Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder With Hyperactivity, Attention Deficit Hyperactivity Disorder Combined, Attention-deficit Hyperactivity
Interventions
CTx-1301 - Dexmethylphenidate 6.25mg, CTx-1301 - Dexmethylphenidate 12.5mg, CTx-1301 - Dexmethylphenidate 18.75mg, CTx-1301 - Dexmethylphenidate 25.0mg, CTx-1301 - Dexmethylphenidate 31.25mg, CTx-1301 - Dexmethylphenidate 37.5mg, Placebo
Drug
Lead sponsor
Cingulate Therapeutics
Industry
Eligibility
6 Years to 12 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Maitland, Florida • Las Vegas, Nevada • North Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced May 22, 2026, 4:09 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Attention-deficit/Hyperactivity Disorder
Interventions
Guanfacine (sustained release)
Drug
Lead sponsor
Neurology Group of Bergen County, P.A.
Other
Eligibility
6 Years to 12 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Ridgewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 1, 2014 · Synced May 22, 2026, 4:09 AM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
ADHD - Inattentive Type, ADHD - Combined Type
Interventions
OROS-Methylphenidate and placebo for inattentive type pts, OROS-Methylphenidate and placebo for combined type pts
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 11 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced May 22, 2026, 4:09 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers
View directory record Official record
Conditions
ADHD - Combined Type, ADHD Predominantly Inattentive Type, ADHD, Predominantly Hyperactive - Impulsive
Interventions
NeuroTrainer
Behavioral
Lead sponsor
NeuroTrainer
Industry
Eligibility
11 Years to 17 Years
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
3
States / cities
Marquette, Michigan • Omaha, Nebraska • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced May 22, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
ADHD, Attention Deficit Hyperactivity Disorder, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined, Attention-deficit Hyperactivity, Attention Deficit Hyper Activity
Interventions
CTx-1301-Dexmethylphenidate 12.5 mg (titration only), CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 37.5 mg (randomized fixed dose), Placebo
Drug
Lead sponsor
Cingulate Therapeutics
Industry
Eligibility
6 Years to 17 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
24
States / cities
Jacksonville, Florida • Maitland, Florida • Orlando, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced May 22, 2026, 4:09 AM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (Combined-subtype)
Interventions
Working memory training, Functional magnetic resonance imaging (fMRI)
Behavioral · Device
Lead sponsor
Hartford Hospital
Other
Eligibility
13 Years to 17 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced May 22, 2026, 4:09 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder Combined
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
Donald Gilbert, MD, MS, FAAN, FAAP
Other
Eligibility
8 Years to 12 Years
Enrollment
214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
2
States / cities
Baltimore, Maryland • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 22, 2026, 4:09 AM EDT